Technology
Health
Pharmaceutical

Lipocine

$2.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.14%) Today
-$0.07 (-3.45%) After Hours

Why Robinhood?

You can buy or sell Lipocine and other stocks, options, ETFs, and crypto commission-free!

About

Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. Read More The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Employees
10
Headquarters
Salt Lake City, Utah
Founded
2011
Market Cap
47.27M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
294.48K
High Today
$2.20
Low Today
$2.12
Open Price
$2.16
Volume
72.20K
52 Week High
$2.64
52 Week Low
$1.03

Collections

Technology
Health
Pharmaceutical
Research And Development
Therapy
2013 IPO
US
North America

News

PR NewswireMar 21

Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference

SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic potential for non-alcoholic steatohepatitis ("NASH") at the ROTH Battle of the NASH Thrones Spring Investor Conference, being held March 28, 2019 in New York City. ROTH Battle of the NASH Thrones Spring Investor Conference Date: Thursday, March 28th Location: Park Hya...

20
PR NewswireMar 14

Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019

SALT LAKE CITY, March 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019. The presentation will highlight the therapeutic potential of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") and non-alcoholic steatohepatitis ("NASH"). ENDO 2019 is being held March 23rd – 26th in New Orleans, LA. Presentation Details Title: Therapeutic Potential of LPCN 1144 in NAFLD...

219
BenzingaMar 12

Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate (NASDAQ:LPCN)

Lipocine Inc (NASDAQ: LPCN) is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate.

267

Earnings

-$0.31
-$0.20
-$0.09
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected May 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.